Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542550 | 0.85 | BTK (0.51) | BTKSYK | |
| SCHEMBL1068769 | 0.80 | BTK (0.65) | BTKSYK | |
| SCHEMBL1542279 | 0.78 | BTK (0.56) | BTKSYK | |
| SCHEMBL1542044 | 0.77 | BTK (0.48) | BTKSYK | |
| SCHEMBL13531782 | 0.75 | BTK (0.52) | BTKSYK | |
| SCHEMBL13547725 | 0.75 | BTK (0.44) | BTKSYK | |
| SCHEMBL4811476 | 0.74 | BTK (0.78) | BTKSYK | |
| SCHEMBL15513135 | 0.73 | BTK (0.45) | BTKSYK | |
| SCHEMBL1070103 | 0.73 | BTK (0.76) | BTK | |
| SCHEMBL4811006 | 0.72 | BTK (0.74) | BTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307418-B1 | NOVEL PHENYLIMIDAZOPYRAZINES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8426409-B2 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426409-B2 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2307418-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010006970-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | MYD88, TLR3, TMEM97 | BTK 373/4885SYK 432/4885 |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | BTK, LCK, LYN | BTK 1/4885SYK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.